Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC

Malignant Neoplasm of Breast Clinical Trial

— NIB  

Official title:

A Phase II One-arm Open-label Neoadjuvant Study of Pembrolizumab in Combination With Nab-paclitaxel Followed by Pembrolizumab in Combination With Epirubicin and Cyclophosphamide in Patients With Triple Negative Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03289819
• Other study ID #: IFG-NIB-01
• Secondary ID: 2016-003102-14U1
• Status: Completed
• Phase: Phase 2
• Start date: March 23, 2018
• Est. completion date: January 22, 2021

Study information

• Verified date: April 2021
• Source: Institut fuer Frauengesundheit
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Despite its aggressiveness and high incidence, to date, no targeted therapies exist for the treatment of triple negative breast cancer (TNBC). Emerging evidence suggests a crucial role of tumor immunology on outcome for this entity. Checkpoint inhibitors like pembrolizumab, which target immune cells within the tumor, might therefore have an important impact on therapy response and outcome in these high risk patients. We propose a phase II study exploring pathological complete response and the safety of the combination of pembrolizumab and nab-paclitaxel as well as the combination of pembrolizumab with epirubicin and cyclophosphamide in the neoadjuvant setting for women with early TNBC. After completion of this study an extension will be determined.

Description:

This is a multicenter, phase II, one-arm, open-label neoadjuvant study of pembrolizumab in combination with nab-paclitaxel followed by pembrolizumab in combination with epirubicin and cyclophosphamide (E/C) in patients with TNBC. Pathological complete response rate at the time of surgery is the primary objective of this study.

In approximately six large breast cancer centers in Germany 50 patients are planned to be enrolled. All patients will undergo state of the art staging and tumor assessments prior to study entry to assess eligibility for the present trial. Eligible and consented patients will receive 12 cycles of weekly nab-paclitaxel i.v. 125 mg/m² BSA q1w in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles pembrolizumab i.v. 200 mg q3w. After the 25th patient has started trial treatment, all further included patients will receive 1 cycle of pembrolizumab i.v. 200 mg q3w monotherapy followed by 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w. Clinical and bioptic tumor assessment will be performed after each treatment phase. Additional imaging, preferably with sonography, will be performed 6 weeks after initiation of taxane and anthracycline therapy to allow for early progress and response monitoring.

Study treatment will be applied until state of the art surgery, onset of unacceptable toxicities, progression or withdrawal of consent. A safety follow-up is planned 120 days after administration of the last dose of trial treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 53
• Est. completion date: January 22, 2021
• Est. primary completion date: August 27, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Written informed consent prior to beginning of trial specific procedures.

2. Subject must be female and aged = 18 years on day of signing informed consent.

3. ECOG(Eastern Cooperative Oncology Group) 0-1

4. Histologically confirmed, early TNBC determined by core biopsy of breast tumor lesion. ER and PR negativity are defined as = 1% of cells expressing hormonal receptors via IHC (immuno-histochemistry) analysis. HER2(human epidermal growth factor receptor 2) negativity is defined as either of the following by local laboratory assessment: In situ hybridization (ISH) non-amplified (ratio = 2.2), or IHC 0 or IHC 1+.

5. Measurable tumor lesion with a size of = 1 cm assessed by sonography or magnetic resonance imaging (MRI) within = 21 days prior to entry. In case of inflammatory disease the extent of inflammation will be measured.

6. Indication for chemotherapy.

7. Multicentric and/or multifocal disease, as well as synchronous bilateral breast cancer, is eligible as long as one measurable lesion meets all inclusion criteria. The investigator has to determine which lesion will be used for tumor evaluation before initiation of treatment.

8. Complete staging work up within 8 weeks prior to entry with no evidence of distant disease, including bilateral mammography, breast ultrasound, chest-X-ray (or chest CT-scan), liver ultrasound (or liver CT-scan or liver MRI) and bone scan.

9. Subjects must provide a core biopsy from tumor lesion at 3 time points (before, after first phase of treatment and at surgery) for central confirmation of TNBC status and biomarker analyses.

10. Adequate organ function, defined as:

Absolute neutrophil count (ANC)= 1.5 x10³/µl, Hemoglobin = 10.0 g/dl OR = 6.2 mmol/l, Platelets = 100 x10³/µl, Creatinine = 1.5 x ULN OR GFR = 30 ml/min, Total bilirubin = 1.5 x ULN, AST (SGOT) and ALT (SGPT) = 1.5 x ULN, Alkaline phosphatase = 2.5 x ULN, International normalized ratio (INR) or prothrombin time (PT) = 1.5 x ULN, Activated partial thromboplastin time (aPTT) = 1.5 x ULN,

11. Female subjects of childbearing potential must have a negative urine pregnancy test within 72 hours prior to study entry and be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication. Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.

Exclusion Criteria:

1. Concurrent participation in a study with an investigational agent/device or within 14 days of study entry.

2. Prior chemotherapy, radiation therapy or small molecule therapy for any reason.

3. Previous malignant disease being disease-free for less than 3 years (except in situ carcinoma of the cervix and basal cell carcinoma of the skin).

4. Pregnancy or lactation.

5. Prior therapy with an anti-PD1, anti-PD L1, anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g. CTLA-4, OX-40, CD137).

6. Active infection requiring systemic therapy.

7. History of (non-infectious) pneumonitis that required steroids or current pneumonitis.

8. Active autoimmune disease or other diseases that requires systemic treatment with corticosteroids or immunosuppressive drugs (physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency is allowed).

9. History of primary or acquired immunodeficiency (including allogenic organ transplant).

10. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).

11. Known history of following infections:

1. Human immunodeficiency virus (HIV)

2. History of acute or chronic Hepatitis B or Hepatitis C

3. Has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted

12. Known congestive heart failure >NYHA I (New York Heart Association) and/or coronary heart disease, angina pectoris, previous history of myocardial infarction, uncontrolled or poorly controlled arterial hypertension (e.g. blood pressure >160/90 mmHg under treatment with two or more antihypertensive drugs), rhythm disorders with clinically significant valvular heart disease.

13. Preexisting motor or sensory neuropathy of a severity grade = 2 by NCI CTCAE v4.0.

14. Known, pathogenic BRCA (breast cancer susceptibility gene) mutation. Note: testing is not mandatory for trial participation.

15. Any other condition in opinion of the investigator that would interfere with applied systemic treatment or other trial procedures.

Related Conditions & MeSH terms

• Breast Neoplasms
• Malignant Neoplasm of Breast
• Neoplasms

Intervention

Drug:
• Pembrolizumab
All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w. After the 25th patient has started trial treatment, all further included patients will receive 1 cycle of pembrolizumab i.v. 200 mg q3w monotherapy followed by 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w.
• nab-paclitaxel
All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
• Epirubicin
All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
• Cyclophosphamide
All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.

Locations

Country	Name	City	State
Germany	Department of Gynecology and Obstetrics, HELIOS Hospital Berlin Buch GmbH	Berlin
Germany	Department for Gynecology and Obstetrics, Marienhospital Bottrop gGmbH	Bottrop	North Rhine-Westphalia
Germany	Department of Gynecology and Obstetrics, Erlangen University Hospital	Erlangen	Bavaria
Germany	Department of Gynecology, Tübingen University Hospital	Tübingen	Baden-Württemberg

Sponsors (3)

Lead Sponsor	Collaborator
Institut fuer Frauengesundheit	Celgene Corporation, Merck Sharp & Dohme Corp.

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Tumor infiltrating lymphocytes (TILs)	Tumor microenvironment prior to and during study treatment. TILs (stroma and intratumoral) in percent as assessed in Denkert et al. 2015, JCO.	Measured from biomaterial collected at baseline, 12 weeks after treatment initiation and at surgery.
Other	Immunohistochemistry	PD1 (Programmed cell death protein 1), PD-L1 (Programmed death-ligand 1), SPARC (Secreted protein acidic and rich in cysteine), Caveolin-1, TIM-3 (T-cell immunoglobulin mucin-3), Lag-3 (Lymphocyte-activation gene 3) will be assessed via immunohistochemistry in percentage of stained cells to total cell count and assesment of immunoreactive score (IRS) for each marker.	Measured from biomaterial collected at baseline, 12 weeks after treatment initiation and at surgery.
Other	Tumor Immunogenicity	Tumor immunogenicity characteristic measured via FACS of the following markers (CD45, CD3, CD4, CD8, CD14, CD19, CD25, CD56, CD127, CD197, HLA-DR, CD45RA, Ki67) in percent of positive cells to total cell count.	Measured from biomaterial collected at baseline, 12 weeks after treatment initiation and at surgery.
Other	Mutational load	Mutational load assessed by Next Generation Sequencing of Germline- and Tumor-DNA in mutations per megabases	Measured from biomaterial collected at baseline, 12 weeks after treatment initiation and at surgery.
Other	Neoepitope Detection	Amount of tumor neoepitopes assessed by Next Generation Sequencing comparing Germline- and Tumor-DNA. Neoepitopes are defined as mutations that lead to aminoacid changes and are found in tumor DNA only.	Measured from biomaterial collected at baseline, 12 weeks after treatment initiation and at surgery.
Other	Cell-free RNA (cfRNA)	Expression levels of specific tumor- and immune-related analytes in cfRNA will be measured by qPCR and possibly other methods and analyzed for correlations with subject outcomes.	Measured from biomaterial collected at baseline, 12 weeks after treatment initiation and at surgery.
Other	Immune Status	Peripheral Blood Mononuclear Cells will be collected from whole peripheral blood and sorted into subsets of T cells and myeloid cells by flow cytometry and then subjected to transcriptomic profilling by deep sequencing.	Measured from biomaterial collected at baseline, 12 weeks after treatment initiation and at surgery.
Other	Circulation Metabolites	Circulating metabolites of host and bacterial metabolites will be assessed in plasma using a multiplex 43-panel ELISA assay.	Measured from biomaterial collected at baseline, 12 weeks after treatment initiation and at surgery.
Other	Microbial burden	Viral, bacterial, fungal, helminth and parasite microbial burden will be assessed by Shotgun Deep Sequencing of cell-free RNA and DNA fragments in plasma.	Measured from biomaterial collected at baseline, 12 weeks after treatment initiation and at surgery.
Other	Microbiome	Stool microbiome will be assessed by Shotgun Deep Sequencing and analyzed for correlations with clinical outcome.	Measured from biomaterial collected at baseline, 12 weeks after treatment initiation and at surgery.
Other	pCR rate after initiation boost	To compare pCR rate in patients receiving a combination of pembrolizumab with nab-paclitaxel and epirubicin/cyclophosphamide chemotherapy and patients receiving 1 cycle of pembrolizumab monotherapy during an initiation boost followed by a combination of pembrolizumab with nab-paclitaxel and epirubicin/cyclophosphamide chemotherapy	Pathological complete response will be assessed at final surgery for patients who received at least two cycles of Pembrolizumab. The rate will be assessed from 30 days until 120 days after last application of medication.
Primary	Pathological Complete Response (pCR) rate	Pathological complete response (pCR) rate, defined as the complete absence of all tumor cells (ypT0/ypN0), absence of invasive tumor (ypT0/is ypN0) and regression grades after study treatment. Pathological complete response is the primary endpoint of this trial and correlates especially well with disease-free survival and overall survival in patients with TNBC. Pathological complete response also serves as a surrogate marker for prognosis in TNBC	Pathological complete response will be assessed at final surgery for patients who received at least two cycles of Pembrolizumab. The rate will be assessed from 30 days until 120 days after last application of medication.
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	The safety endpoints for the study will include rate of AE/SAEs and fatal SAEs, causality and outcome of AE/SAEs, rate of treatment discontinuations and reasons, changes in vital signs, laboratory values etc. Grading of AE/SAEs will be based on NCI CTCAE v4.0.	The adverse events will be assessed from first infusion until 120 days after last application of medication.
Secondary	Clinical Response	To evaluate the efficacy of the treatment as measured by clinical response (objective response rate by 30 %) 6 weeks after the start of each sequential chemotherapy (nab-paclitaxel and E/C) and at the time of the surgery	Every 6 weeks from date of first medication administration until the date of first documented progression, surgery or date of death from any cause, whichever came first, assessed up to 120 days after last dose.
Secondary	EORTC QLQ-BR23	To evaluate changes in health related quality of life (QoL) assessments from baseline in all subjects using the EORTC Breast Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR23)	Every two weeks from first administration of trial medication through study completion, up to 120 days after administration of last medication.
Secondary	EORTC QLQ-C30	To evaluate changes in health related quality of life (QoL) assessments from baseline in all subjects using Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)	Every two weeks from first administration of trial medication through study completion, up to 120 days after administration of last medication.